Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gan and Lee PharmaceuticalsSHSE:603087 -2.27%90 Return-on-Tangible-Equity is 17.42% as of Jun. 2026, which is 2% below its 10-year median of 17.75. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review. Among 754 Medical Devices & Instruments companies, Gan and Lee Pharmaceuticals ranks better than 69.1% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Gan and Lee Pharmaceuticals's annualized net income for the quarter that ended in Jun. 2026 was ¥1,669 Mil. Gan and Lee Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ¥9,584 Mil. Therefore, Gan and Lee Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 17.42%.
The historical rank and industry rank for Gan and Lee Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:603087'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -4.92 Med: 17.75 Max: 45.24
Current: 11.97
During the past 13 years, Gan and Lee Pharmaceuticals's highest Return-on-Tangible-Equity was 45.24%. The lowest was -4.92%. And the median was 17.75%.
SHSE:603087's Return-on-Tangible-Equity is ranked better than 69.1% of 754
companies
in the Medical Devices & Instruments industry
Industry Median: 4.855
vs SHSE:603087: 11.97
Gan and Lee Pharmaceuticals (SHSE:603087) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Gan and Lee Pharmaceuticals Return-on-Tangible-Equity Related Terms
Gan and Lee Pharmaceuticals Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gan and Lee Pharmaceuticals Return-on-Tangible-Equity Chart
SHSE:603087 vs ISRG, BDX, RMD: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gan and Lee Pharmaceuticals Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Gan and Lee Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 17.42% mean?
Gan and Lee Pharmaceuticals (SHSE:603087) has a Return-on-Tangible-Equity of 17.42% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gan and Lee Pharmaceuticals and its competitors. This is near median its historical median of 17.75. According to the industry distribution chart, Gan and Lee Pharmaceuticals ranks #233 out of 754 companies in the Medical Devices & Instruments industry, placing it in the top 30.9%.
Is Gan and Lee Pharmaceuticals' Return-on-Tangible-Equity too high?
Gan and Lee Pharmaceuticals' current Return-on-Tangible-Equity of 17.42% is near median its 10-year median of 17.75. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.86. Gan and Lee Pharmaceuticals' value of 17.42% is 258.8% above this industry median. Based on the distribution chart, Gan and Lee Pharmaceuticals ranks #233 out of 754 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gan and Lee Pharmaceuticals ranks #233 out of 754 companies for Return-on-Tangible-Equity. This puts Gan and Lee Pharmaceuticals in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.86. Gan and Lee Pharmaceuticals' value of 17.42% is 258.8% above this benchmark. While the company's 10-year median is 17.75 vs. the industry median of 4.86, Gan and Lee Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.86, based on 754 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current Return-on-Tangible-Equity of 17.42% is 258.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gan and Lee Pharmaceuticals and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current Return-on-Tangible-Equity is 17.42%, which is near median its own 10-year median of 17.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current Return-on-Tangible-Equity is 17.42%, which is near median its 10-year median of 17.75 and 258.8% above the Medical Devices & Instruments industry median of 4.86. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Return-on-Tangible-Equity is 17.42% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00.
GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.
Key valuation signals for SHSE:603087:
Return-on-Tangible-Equity: 17.42% (near median its 10-year median of 17.75)
GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
Industry Position: 258.8% above the Medical Devices & Instruments median (#233 of 754)
No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603087 has been successfully added to your 
